Key Message
Molecular and serological assays for SARS-CoV-2 are being developed and implemented at an exponential rate. This suite of complementary tests will inform crucial decisions by healthcare providers and policy makers and understanding their strengths and limitations will be critical to their judicious application to treatment and public health strategies.